Another question is whether other parameters such as inflammatory cytokines (e.g. IL-1β, IL-6, IL-8), placental growth factor or circulating tumour cells should have been explored to gain better insight in pharmacodynamic alterations at the tumoural level (Jain et al, 2009). The gene discussed is IL1B; the disease is neoplasm.